These results suggest that survivin is involved in chemoresistance to gemcitabine and osimertinib in cancer cells and the CSCs of NSCLC and pancreatic cancer, and also that spironolactone chemosensitizes NSCLC, pancreatic cancer, and glioblastoma cells to gemcitabine and osimertinib most likely through the suppression of survivin. Here, BIRC5 is linked to pancreatic neoplasm.